REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement with AbbVie.

The biotech firm previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan — a dramatic turnaround from a net loss of 4.5 billion yuan in the prior-year period. The stellar performance was primarily driven by sustained domestic sales growth of its core products Telitacicept and Disitamab Vedotin, alongside a significant boost in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which includes an upfront payment of 650 million USD and a total deal value of up to 5.6 billion USD.

Additional positive catalysts include the recently published new National Essential Drug List, which is expected to create further volume expansion opportunities for the company's key products. The broader biotech sector also showed strength, with peers such as 3SBIO, AKESO, and INNOVENT BIO posting gains, creating a favorable spillover effect for REMEGEN.